Using 2.93 fb–1 of e+e– collision data collected at a center-of-mass energy of 3.773 GeV with the BESIII detector, the first observation of the doubly Cabibbo-suppressed decay D+ → K+π+π–π0 is ...reported. After removing decays that contain narrow intermediate resonances, including D+ → K+η , D+ → K+ω, and D+ → K+Φ, the branching fraction of the decay D+ → K+π+π–π0 is measured to be (1.13 ± 0.08stat ± 0.03syst) × 10–3. The ratio of branching fractions of D+ → K+π+π–π0 over D+ → K–π+π+π0 is found to be (1.81 ± 0.15)%, which corresponds to (6.28 ± 0.52) tan4 θC, where θC is the Cabibbo mixing angle. This ratio is significantly larger than the corresponding ratios for other doubly Cabibbo-suppressed decays. The asymmetry of the branching fractions of charge-conjugated decays D± → K±π±π∓π0 is also determined, and no evidence for CP violation is found. In addition, the first evidence for the D+ → K+ω decay, with a statistical significance of 3.3σ, is presented and the branching fraction is measured to be B(D+ → K+ω) = (5.7 $^{+2.5}_{–2.1 stat}$ ± 0. 2syst) × 10–5.
Full text
Available for:
CMK, CTK, FMFMET, IJS, NUK, PNG, UL, UM
Based on e+e- collision data sample corresponding to an integrated luminosity of 2.93 fb-1 taken at a center-of-mass energy of 3.773 GeV by the BESIII detector, we report the measurements of the ...absolute branching fractions of D0 → K+K-π0π0 , D0 → KS0KS0π+π- , D0 → KS0K-π+π0 , D0 → KS0K+π-π0 , D+ → K+K-π+π0 , D+ → KS0K+π0π0 , D+ → KS0K-π+π+ , D+ → KS0K+π+π- , and D+ → KS0KS0π+π0 . The decays D0 → K+K-π0π0 , D0 → KS0K-π+π0 , D0 → KS0K+π-π0 , D+ → KS0KS0π+π0 , and D+ → KS0K+π0π0 are observed for the first time. The branching fractions of the decays D0 → KS0KS0π+π- , D+ → K+K-π+π0 , D+ → KS0K-π+π+ , and D+ → KS0K+π+π- are measured with improved precision compared to the world-average values.
Full text
Available for:
CMK, CTK, FMFMET, IJS, NUK, PNG, UM
To investigate the role of donor change in the second hematopoietic stem cell transplantation (HSCT2) for hematological relapse of malignant hematology after the first transplantation (HSCT1) .
We ...retrospectively analyzed patients with relapsed hematological malignancies who received HSCT2 at our single center between Mar 1998 and Dec 2020. A total of 70 patients were enrolled49 males and 21 females; median age, 31.5 (3-61) yr.
Forty-nine male and 21 female patients were enrolled in the trial. At the time of HSCT2, the median age was 31.5 (3-61) years old. Thirty-one patients were diagnosed with acute myeloid leukemia, 23 patients with ALL, and 16 patients with MDS or other malignant hematology disease. Thirty patients had HSCT2 with donor change, and 40 patients underwent HSCT2 without donor change. The median relapse time after HSCT1 was 245.5 (26-2 905) days. After HSCT2, 70 patients had neutrophil engraftment, and 62 (88.6%) had platelet engraftment. The cumulative incidence of platelet engraftment was
OBJECTIVETo explore the relationship between drug treatment and outcomes in patients with late-onset severe pneumonia (LOSP) after allogeneic stem cell transplantation (allo-SCT). METHODSWe ...retrospectively analyzed the effects of the initiation time of treatment drugs, especially antiviral drugs and glucocorticoids on the clinical outcomes in 82 patients between January 2016 and August 2021 who developed LOSP after allo-SCT in Peking University People's Hospital. Univariate analysis was performed by Mann-Whitney U test and χ2 test, and multivariate analysis was performed by Logistic regression. When multiple groups (n>2) were involved in the χ2 test, Bonferroni correction was used for the level of significance test. RESULTSOf all 82 patients in this study, the median onset time of LOSP was 220 d (93-813 d) after transplantation, and the 60-day survival rate was 58.5% (48/82). The median improvement time of the survival patients was 18 d (7-44 d), while the median death time of the died patients was 22 d (2-53
PDF
